Genmab Announces Appointment of David Eatwell as New Chief Financial
Officer Summary: Genmab Announces the Appointment of David A. Eatwell as Chief
COPENHAGEN, Denmark, June 2 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) today announced that David A. Eatwell has been appointed Chief Financial Officer of the company. Mr. Eatwell will be responsible for overseeing the financial and accounting activities of the company.
David A. Eatwell, 47, joins Genmab with extensive experience and a proven track record in leading international life science businesses, having spent 15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwell served as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD 1.8 billion leading provider of manufacturing and packaging services for the pharmaceutical and biotech industry, with 33 facilities in 12 countries and 10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO of Cardinal Health, Inc., a fortune 20 global manufacturer and distributor of healthcare products and services, where he spearheaded the USD 3.3 billion sale of the Pharmaceutical Technologies and Services division to The Blackstone Group and was instrumental in creating the framework and building the infrastructure to support the newly created company, Catalent Pharma Solutions, Inc. Mr. Eatwell is a Chartered Accountant.
Mr. Eatwell is replacing Bo Kruse who has decided to seek new challenges elsewhere, but will during a transitional period be available for the company.
"We are very excited to have David Eatwell on board to be part of our
Senior Management team and we are looking forward to working with him. We
also wish to thank Bo Kruse for his many years of dedicated service to
Genmab, and important contributions to the company. We wish Bo Kruse the
best of luck in his future endeavors and would like t
|SOURCE Genmab A/S|
Copyright©2008 PR Newswire.
All rights reserved